Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), Cancer Type (Hematological Malignancy), By End-use (Hospitals), By Region, And Segment Forecasts, 2023

The global minimal residual disease testing market size is expected to reach USD 4.50 billion by 2030, at a CAGR of 11.45% from 2023 to 2030, according to a new report by Grand View Research, Inc. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime.

MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK's hematology therapeutics.

Surgical removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a 'software-as-a-medical-device' MRD test in Europe.

Cancer therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective treatment. For instance, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic for increasing access to MRD monitoring in blood cancers. Moreover, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera's diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.

Minimal Residue Disease Testing Market Report Highlights:

The flow cytometry segment held a dominant share in the minimal residual disease testing market in 2022 owing to the high sensitivity and wide applicability of MRD testing

The hematological malignancy segment is projected to grow at the fastest rate over the forecast period owing to the increasing prevalence of hematological malignancy

The hospitals and specialty clinics segment is the highest revenue-generating segment in 2022 owing to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics

North America dominated the minimal residual disease testing market in 2022, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape

Product Code: GVR-4-68040-016-3

Chapter 1 Methodology and Scope

1.1 Market Segmentation
- 1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 Secondary Sources
- 1.3.3 Primary Research
- 1.3.4 Details Of Primary Research
1.4 Information Or Data Analysis
- 1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
- 1.6.1 Commodity Flow Analysis
  - 1.6.1.1 Approach 1: Commodity Flow Approach
  - 1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: Cagr Calculation
1.8 Research Assumptions
1.9 List Of Secondary Sources
1.10 List Of Primary Sources
1.11 Objectives
- 1.11.1 Objective 1:
- 1.11.2 Objective 2:
1.12 List Of Abbreviations

Chapter 2 Executive Summary

2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot

Chapter 3 Market Variables, Trends & Scope

3.1 Minimal Residual Disease Testing Market Lineage Outlook
- 3.1.1 Parent Market Outlook
  - 3.1.1.1 Cellular Health Screening Market Outlook
  - 3.1.1.2 In Vitro Diagnostics Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 Market Driver Analysis
- 3.3.1 Increasing Prevalence Of Cancer
- 3.3.2 Growing Investments In Mrd Testing
- 3.3.3 Growing Investment For Research
3.4 Market Restraint Analysis
- 3.4.1 High-Cost Associated With Mrd Testing
- 3.4.2 Complex Regulatory Framework Associated With Mrd Testing
3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
3.6 Porter's Five Forces Analysis
3.7 Regulatory Framework

Chapter 4 Minimal Residual Disease Testing Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)

4.1 Definition And Scope
4.2 Minimal Residual Disease Testing Market: Technology Movement Analysis
- 4.2.1 Flow Cytometry
  - 4.2.1.1 Flow Cytometry Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.2.2 Polymerase Chain Reaction (Pcr)
  - 4.2.2.1 Polymerase Chain Reaction (Pcr) Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.2.3 Next Generation Sequencing (Ngs)
  - 4.2.3.1 Next Generation Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.2.4 Others
  - 4.2.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Minimal Residual Disease Testing Market - Segment Analysis, By Cancer Type, 2018 - 2030 (USD Million)

5.1 Minimal Residual Disease Testing Market: Cancer Type Movement Analysis
- 5.1.1 Hematological Malignancy
  - 5.1.1.1 Hematological Malignancy Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 5.1.2 Solid Tumors
  - 5.1.2.1 Solid Tumors Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Minimal Residual Disease Testing Market - Segment Analysis, By Business, 2018 - 2030 (USD Million)

6.1 Definition And Scope
6.2 Minimal Residual Disease Testing Market: Business Movement Analysis
- 6.2.1 Hospitals And Speciality Clinics
  - 6.2.1.1 Hospitals And Speciality Clinics Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.2.2 Diagnostic Laboratories
  - 6.2.2.1 Diagnostic Laboratories Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.2.3 Academic And Research Institutes
  - 6.2.3.1 Research Institutes Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.2.4 Others
  - 6.2.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Minimal Residual Disease Testing Market - Regional Business Analysis

7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2022 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
- 7.5.1 North America
- 7.5.2 Europe
- 7.5.3 Asia Pacific
- 7.5.4 Latin America
- 7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
7.7 North America
- 7.7.1 North America Market Estimates And Forecast, 2018 - 2030 (USD MILLION)
- 7.7.2 U.S.
  - 7.7.2.1 U.S. Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.7.2.2 Key country Dynamics
  - 7.7.2.3 Regulatory Framework
  - 7.7.2.4 Competitive Scenario
  - 7.7.2.5 Recent Developments
  - 7.7.2.6 Investments Scenario
- 7.7.3 Canada
  - 7.7.3.1 Canada Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.7.3.2 Key country Dynamics
  - 7.7.3.3 Regulatory Framework
  - 7.7.3.4 Competitive Scenario
  - 7.7.3.5 Recent Developments
  - 7.7.3.6 Investments Scenario
7.8 Europe
- 7.8.1 Europe Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
- 7.8.2 UK
  - 7.8.2.1 UK Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.8.2.2 Key country Dynamics
  - 7.8.2.3 Regulatory Framework
  - 7.8.2.4 Competitive Scenario
  - 7.8.2.5 Recent Developments
  - 7.8.2.6 Investments Scenario
- 7.8.3 Germany
  - 7.8.3.1 Germany Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.8.3.2 Key country Dynamics
  - 7.8.3.3 Regulatory Framework
  - 7.8.3.4 Competitive Scenario
  - 7.8.3.5 Recent Developments
  - 7.8.3.6 Investments Scenario
- 7.8.4 Spain
  - 7.8.4.1 Spain Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.8.4.2 Key country Dynamics
  - 7.8.4.3 Regulatory Framework
  - 7.8.4.4 Competitive Scenario
  - 7.8.4.5 Recent Developments
  - 7.8.4.6 Investments Scenario
- 7.8.5 France
  - 7.8.5.1 France Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.8.5.2 Key country Dynamics
  - 7.8.5.3 Regulatory Framework
  - 7.8.5.4 Competitive Scenario
  - 7.8.5.5 Recent Developments
  - 7.8.5.6 Investments Scenario
- 7.8.6 Italy
  - 7.8.6.1 Italy Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.8.6.2 Key country Dynamics
  - 7.8.6.3 Regulatory Framework
  - 7.8.6.4 Competitive Scenario
  - 7.8.6.5 Recent Developments
  - 7.8.6.6 Investments Scenario
- 7.8.7 Denmark
  - 7.8.7.1 Denmark Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.8.7.2 Key country Dynamics
  - 7.8.7.3 Regulatory Framework
  - 7.8.7.4 Competitive Scenario
  - 7.8.7.5 Recent Developments
  - 7.8.7.6 Investments Scenario
- 7.8.8 Sweden
  - 7.8.8.1 Sweden Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.8.8.2 Key country Dynamics
  - 7.8.8.3 Regulatory Framework
  - 7.8.8.4 Competitive Scenario
  - 7.8.8.5 Recent Developments
  - 7.8.8.6 Investments Scenario
- 7.8.9 Norway
  - 7.8.9.1 Norway Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.8.9.2 Key country Dynamics
  - 7.8.9.3 Regulatory Framework
  - 7.8.9.4 Competitive Scenario
  - 7.8.9.5 Recent Developments
  - 7.8.9.6 Investments Scenario
7.9 Asia Pacific
- 7.9.1 Asia-Pacific Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
- 7.9.2 Japan
  - 7.9.2.1 Japan Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.9.2.2 Key country Dynamics
  - 7.9.2.3 Regulatory Framework
  - 7.9.2.4 Competitive Scenario
  - 7.9.2.5 Recent Developments
  - 7.9.2.6 Investments Scenario
- 7.9.3 China
  - 7.9.3.1 China Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.9.3.2 Key country Dynamics
  - 7.9.3.3 Regulatory Framework
  - 7.9.3.4 Competitive Scenario
  - 7.9.3.5 Recent Developments
  - 7.9.3.6 Investments Scenario
- 7.9.4 India
  - 7.9.4.1 India Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.9.4.2 Key country Dynamics
  - 7.9.4.3 Regulatory Framework
  - 7.9.4.4 Competitive Scenario
  - 7.9.4.5 Recent Developments
  - 7.9.4.6 Investments Scenario
- 7.9.5 South Korea
  - 7.9.5.1 South Korea Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.9.5.2 Key country Dynamics
  - 7.9.5.3 Regulatory Framework
  - 7.9.5.4 Competitive Scenario
  - 7.9.5.5 Recent Developments
  - 7.9.5.6 Investments Scenario
- 7.9.6 Thailand
  - 7.9.6.1 Thailand Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.9.6.2 Key country Dynamics
  - 7.9.6.3 Regulatory Framework
  - 7.9.6.4 Competitive Scenario
  - 7.9.6.5 Recent Developments
  - 7.9.6.6 Investments Scenario
- 7.9.7 Australia
  - 7.9.7.1 Australia Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.9.7.2 Key country Dynamics
  - 7.9.7.3 Regulatory Framework
  - 7.9.7.4 Competitive Scenario
  - 7.9.7.5 Recent Developments
  - 7.9.7.6 Investments Scenario
7.10 Latin America
- 7.10.1 Latin America Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
- 7.10.2 Brazil
  - 7.10.2.1 Brazil Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.10.2.2 Key country Dynamics
  - 7.10.2.3 Regulatory Framework
  - 7.10.2.4 Competitive Scenario
  - 7.10.2.5 Recent Developments
  - 7.10.2.6 Investments Scenario
- 7.10.3 Mexico
  - 7.10.3.1 Mexico Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.10.3.2 Key country Dynamics
  - 7.10.3.3 Regulatory Framework
  - 7.10.3.4 Competitive Scenario
  - 7.10.3.5 Recent Developments
  - 7.10.3.6 Investments Scenario
- 7.10.4 Argentina
  - 7.10.4.1 Argentina Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.10.4.2 Key country Dynamics
  - 7.10.4.3 Regulatory Framework
  - 7.10.4.4 Competitive Scenario
  - 7.10.4.5 Recent Developments
  - 7.10.4.6 Investments Scenario
7.11 MEA
- 7.11.1 MEA Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
- 7.11.2 South Africa
  - 7.11.2.1 South Africa Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.11.2.2 Key country Dynamics
  - 7.11.2.3 Regulatory Framework
  - 7.11.2.4 Competitive Scenario
  - 7.11.2.5 Recent Developments
  - 7.11.2.6 Investments Scenario
- 7.11.3 Saudi Arabia
  - 7.11.3.1 Saudi Arabia Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.11.3.2 Key country Dynamics
  - 7.11.3.3 Regulatory Framework
  - 7.11.3.4 Competitive Scenario
  - 7.11.3.5 Recent Developments
  - 7.11.3.6 Investments Scenario
- 7.11.4 UAE
  - 7.11.4.1 UAE Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.11.4.2 Key country Dynamics
  - 7.11.4.3 Regulatory Framework
  - 7.11.4.4 Competitive Scenario
  - 7.11.4.5 Recent Developments
  - 7.11.4.6 Investments Scenario
- 7.11.5 Kuwait
  - 7.11.5.1 Kuwait Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  - 7.11.5.2 Key country Dynamics
  - 7.11.5.3 Regulatory Framework
  - 7.11.5.4 Competitive Scenario
  - 7.11.5.5 Recent Developments
  - 7.11.5.6 Investments Scenario

Chapter 8 Minimal Residual Disease Testing Market - Competitive Analysis

8.1 Company/Competition Categorization (Key Innovators, Market leaders, Emerging Players)
8.2 Strategy Framework
8.3 Market Participation Categorization
8.4 Recent Developments & Impact Analysis, by Key Market Participants
8.5 Company Position Analysis
8.6 List of Distributors
- 8.6.1 Key Customers
- 8.6.2 Public Companies
- 8.6.3 Private Companies

Chapter 9 Company Profiles

9.1 Company Profiles
- 9.1.1 EXACT SCIENCES CORPORATION,
  - 9.1.1.1 Company Overview
  - 9.1.1.2 Financial Performance
  - 9.1.1.3 Product Benchmarking
  - 9.1.1.4 Strategic Initiatives
- 9.1.2 GRAIL, LLC
  - 9.1.2.1 Company Overview
  - 9.1.2.2 Financial performance
  - 9.1.2.3 Product Benchmarking
  - 9.1.2.4 Strategic Initiatives
- 9.1.3 VERACYTE, INC.
  - 9.1.3.1 Company Overview
  - 9.1.3.2 Financial performance
  - 9.1.3.3 Product Benchmarking
  - 9.1.3.4 Strategic Initiatives
- 9.1.4 NATERA, INC.
  - 9.1.4.1 Company Overview
  - 9.1.4.2 Financial performance
  - 9.1.4.3 Product Benchmarking
  - 9.1.4.4 Strategic Initiatives
- 9.1.5 GUARDANT HEALTH
  - 9.1.5.1 Company Overview
  - 9.1.5.2 Financial performance
  - 9.1.5.3 Product Benchmarking
  - 9.1.5.4 Strategic Initiatives
- 9.1.6 F. HOFFMANN-LA ROCHE LTD
  - 9.1.6.1 Company Overview
  - 9.1.6.2 Financial performance
  - 9.1.6.3 Product Benchmarking
  - 9.1.6.4 Strategic Initiatives
- 9.1.7 FOUNDATION MEDICINE, INC.
  - 9.1.7.1 Company Overview
  - 9.1.7.2 Financial performance
  - 9.1.7.3 Product Benchmarking
  - 9.1.7.4 Strategic Initiatives
- 9.1.8 QIAGEN
  - 9.1.8.1 Company Overview
  - 9.1.8.2 Financial performance
  - 9.1.8.3 Product Benchmarking
  - 9.1.8.4 Strategic Initiatives
- 9.1.9 MDXHEALTH
  - 9.1.9.1 Company Overview
  - 9.1.9.2 Financial performance
  - 9.1.9.3 Product Benchmarking
  - 9.1.9.4 Strategic Initiatives
- 9.1.10 BIO-TECHNE.
  - 9.1.10.1 Company Overview
  - 9.1.10.2 Financial performance
  - 9.1.10.3 Product Benchmarking
  - 9.1.10.4 Strategic Initiatives

Product Code: GVR-4-68040-016-3

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Regulatory Framework
Table 4 Global Minimal Residual Disease Testing Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 6 Global Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 7 Global Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 8 North America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 10 North America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 11 North America Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 12 U.S. Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 13 U.S. Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 14 U.S. Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 15 Canada Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 16 Canada Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 17 Canada Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 18 Europe Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 19 Europe Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 20 Europe Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 21 Europe Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 22 UK Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 23 UK Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 24 UK Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 25 Germany Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 26 Germany Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 27 Germany Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 28 France Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 29 France Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 30 France Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 31 Spain Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 32 Spain Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 33 Spain Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 34 Italy Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 35 Italy Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 36 Italy Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 37 Denmark Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 38 Denmark Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 39 Denmark Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 40 Sweden Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 41 Sweden Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 42 Sweden Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 43 Norway Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 44 Norway Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 45 Norway Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 50 Japan Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 51 Japan Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 52 Japan Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 53 China Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 54 China Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 55 China Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 56 Australia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 57 Australia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 58 Australia Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 59 Thailand Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 60 Thailand Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 61 Thailand Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 62 India Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 63 India Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 64 India Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 65 South Korea Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 66 South Korea Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 67 South Korea Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 68 Latin America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 69 Latin America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 70 Latin America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 71 Latin America Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 72 Mexico Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 73 Mexico Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 74 Mexico Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 75 Brazil Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 76 Brazil Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 77 Brazil Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 78 Argentina Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 79 Argentina Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 80 Argentina Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 81 MEA Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 82 MEA Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 83 MEA Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 84 MEA Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 85 South Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 86 South Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 87 South Africa Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 90 Saudi Arabia Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 91 UAE Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 92 UAE Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 93 UAE Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
Table 94 Kuwait Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 95 Kuwait Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 96 Kuwait Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Gastroesophageal Reflux Disease Therapeutics Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter's Five Forces Analysis
Fig. 14 Market Penetration & Growth Prospect Mapping
Fig. 15 Minimal residual disease testing market: Technology outlook and key takeaways
Fig. 16 Minimal residual disease testing market: Technology movement analysis & market share 2022 & 2030
Fig. 17 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Polymerase chain reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Next generation sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Minimal residual disease testing market: Cancer type outlook and key takeaways
Fig. 22 Minimal residual disease testing market: Cancer type movement analysis & market share 2022 & 2030
Fig. 23 Haematological malignancy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Minimal residual disease testing market: End-Use outlook and key takeaways
Fig. 26 Minimal residual disease testing market: End-Use movement analysis & market share 2022 & 2030
Fig. 27 Hospitals and specialty clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Academic and research institutes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Regional Marketplace: Key Takeaways
Fig. 32 Regional Outlook, 2022 & 2030
Fig. 33 Regional Market Dashboard
Fig. 34 Regional Market Place: Key Takeaways
Fig. 35 North America, SWOT Analysis
Fig. 36 Europe, SWOT Analysis
Fig. 37 Asia Pacific, SWOT Analysis
Fig. 38 Latin America, SWOT Analysis
Fig. 39 MEA, SWOT Analysis
Fig. 40 North America
Fig. 41 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 42 U.S.
Fig. 43 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 44 Canada
Fig. 45 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 46 Europe
Fig. 47 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 48 UK
Fig. 49 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 50 Germany
Fig. 51 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 52 France
Fig. 53 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 54 Italy
Fig. 55 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 56 Spain
Fig. 57 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 58 Denmark
Fig. 59 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 60 Sweden
Fig. 61 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 62 Norway
Fig. 63 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 64 Asia Pacific
Fig. 65 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 66 Japan
Fig. 67 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 68 China
Fig. 69 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 70 India
Fig. 71 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 72 Australia
Fig. 73 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 74 Thailand
Fig. 75 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 76 South Korea
Fig. 77 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 78 Latin America
Fig. 79 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 80 Brazil
Fig. 81 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 82 Mexico
Fig. 83 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 84 Argentina
Fig. 85 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 86 MEA
Fig. 87 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 88 South Africa
Fig. 89 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 90 Saudi Arabia
Fig. 91 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 92 UAE
Fig. 93 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 94 Kuwait
Fig. 95 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 96 Strategy Mapping

Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), Cancer Type (Hematological Malignancy), By End-use (Hospitals), By Region, And Segment Forecasts, 2023 - 2030

Description

Table of Contents

List of Tables

Minimal Residue Disease Testing Market Growth & Trends:

Minimal Residue Disease Testing Market Report Highlights:

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope

Chapter 4 Minimal Residual Disease Testing Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)

Chapter 5 Minimal Residual Disease Testing Market - Segment Analysis, By Cancer Type, 2018 - 2030 (USD Million)

Chapter 6 Minimal Residual Disease Testing Market - Segment Analysis, By Business, 2018 - 2030 (USD Million)

Chapter 7 Minimal Residual Disease Testing Market - Regional Business Analysis

Chapter 8 Minimal Residual Disease Testing Market - Competitive Analysis

Chapter 9 Company Profiles

List of Tables

List of Figures